Savara’s (SVRA) “Buy” Rating Reiterated at HC Wainwright

by · The Cerbat Gem

HC Wainwright reiterated their buy rating on shares of Savara (NASDAQ:SVRA – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. The brokerage currently has a $10.00 target price on the stock. HC Wainwright also issued estimates for Savara’s FY2025 earnings at ($0.46) EPS, FY2026 earnings at ($0.34) EPS, FY2027 earnings at $0.01 EPS and FY2028 earnings at $0.23 EPS.

Several other equities analysts have also commented on the company. Oppenheimer upped their target price on Savara from $11.00 to $15.00 and gave the company an outperform rating in a research note on Wednesday, June 26th. Guggenheim raised their target price on shares of Savara from $8.00 to $10.00 and gave the stock a buy rating in a research report on Thursday, June 27th. Finally, JMP Securities restated a market outperform rating and issued a $9.00 target price on shares of Savara in a report on Monday, September 9th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, Savara currently has a consensus rating of Buy and a consensus target price of $11.17.

Read Our Latest Stock Report on Savara

Savara Stock Performance

NASDAQ SVRA opened at $3.82 on Tuesday. The business has a fifty day moving average of $4.28 and a 200-day moving average of $4.44. Savara has a fifty-two week low of $3.12 and a fifty-two week high of $5.70. The stock has a market cap of $527.88 million, a price-to-earnings ratio of -10.32 and a beta of 0.97. The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26.

Savara (NASDAQ:SVRA – Get Free Report) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). As a group, analysts predict that Savara will post -0.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Savara

Several institutional investors and hedge funds have recently modified their holdings of SVRA. Superstring Capital Management LP purchased a new stake in shares of Savara during the fourth quarter valued at approximately $3,827,000. Wellington Management Group LLP acquired a new position in Savara in the 4th quarter worth $9,683,000. Sivia Capital Partners LLC purchased a new position in Savara in the 4th quarter valued at about $169,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Savara by 66.3% during the first quarter. China Universal Asset Management Co. Ltd. now owns 26,035 shares of the company’s stock valued at $130,000 after acquiring an additional 10,381 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its stake in shares of Savara by 92.3% during the first quarter. BNP Paribas Financial Markets now owns 73,494 shares of the company’s stock valued at $366,000 after acquiring an additional 35,269 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Company Profile

(Get Free Report)

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Further Reading